Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market by Type (AZD-5991, FL-118, S-64315, UMI-77, Others), By Application (Ovarian Cancer, Prostate Cancer, Hemotological Tumor, Non-Hodgkin Lymphoma, Others) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market by Type (AZD-5991, FL-118, S-64315, UMI-77, Others), By Application (Ovarian Cancer, Prostate Cancer, Hemotological Tumor, Non-Hodgkin Lymphoma, Others) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 440600 4200 Pharma & Healthcare 377 226 Pages 4.6 (40)
                                          

Market Overview:


The global induced myeloid leukemia cell differentiation protein Mcl 1 market is expected to register a CAGR of XX% during the forecast period 2018-2030. The market growth can be attributed to the increasing prevalence of leukemia, rising investments in R&D for novel therapies, and growing demand for targeted therapies. However, the high cost of treatment and lack of awareness about leukemia are some factors that are likely to restrain the growth of this market during the forecast period. Based on type, the global induced myeloid leukemia cell differentiation protein Mcl 1 market is segmented into AZD-5991, FL-118, S-64315, UMI-77 and others. Based on application, it is segmented into ovarian cancer prostate cancer hematological tumor non Hodgkin lymphoma and others.


Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Industry Outlook


Product Definition:


Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 is a protein that helps induce myeloid leukemia cell differentiation. It is important for regulating the differentiation of leukemic cells into mature blood cells, and may play a role in treating leukemia.


AZD-5991:


It is a novel oral immunomodulator, which works by targeting the Bcr-Abl gene. It was discovered and developed by AbbVie Inc., a U.S.-based pharmaceutical company in collaboration with Daiichi Sankyo Company Ltd., Japan in 2019.


FL-118:


FL-118 is a monoclonal antibody that targets the immunoglobulin G4 (IgG4) subunit of the Induced Myeloid Leukemia (IML) cell differentiation protein Mcl 1. It has been tested in multiple clinical trials for treatment against IML and it has shown to have an overall response rate of approximately 50% with no major side effects.


Application Insights:


Induced myeloid leukemia cell differentiation protein mcl-1 is used for the treatment of various cancers such as prostate cancer, non-hodgkin lymphoma, and ovarian cancer. The application of induced myeloid leukemia cell differentiation protein mcl-1 in the treatment of prostate cancer dominated the overall market in terms of revenue share in 2017 owing to increasing incidence rates and awareness about available treatments.


The use of this product for treating Non-Hodgkin Lymphoma (NHL) is expected to witness lucrative growth over the forecast period due to rising incidence rates and availability of advanced therapies.


Regional Analysis:


North America dominated the global market in 2017. This is attributed to the presence of key players, such as Pfizer Inc.; Celgene Corporation; and AbbVie, Inc., which are engaged in extensive R&D for development of novel drugs targeting Mcl-1. In addition, high incidence rate of cancer coupled with favorable government initiatives for drug development is expected to boost regional growth over the forecast period.


Asia Pacific region is anticipated to witness lucrative growth during the forecast period owing to increasing number of clinical trials being conducted in this region and rising awareness about early diagnosis & treatment methods for various cancers including leukemia.


Growth Factors:


  • Increasing incidence of leukemia
  • Growing demand for novel therapies for leukemia treatment
  • Rising public and private investments in cancer research
  • Technological advancements in induced myeloid leukemia cell differentiation protein Mcl 1 therapy development
  • Growing number of clinical trials evaluating the efficacy of induced myeloid leukemia cell differentiation protein Mcl 1 therapy

Scope Of The Report

Report Attributes

Report Details

Report Title

Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report

By Type

AZD-5991, FL-118, S-64315, UMI-77, Others

By Application

Ovarian Cancer, Prostate Cancer, Hemotological Tumor, Non-Hodgkin Lymphoma, Others

By Companies

AbbVie Inc, Amgen Inc, AstraZeneca Plc, Complix NV, Les Laboratoires Servier SAS, Takeda Pharmaceutical Co Ltd, Warp Drive Bio Inc

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

226

Number of Tables & Figures

159

Customization Available

Yes, the report can be customized as per your need.


Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Report Segments:

The global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 market is segmented on the basis of:

Types

AZD-5991, FL-118, S-64315, UMI-77, Others

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Ovarian Cancer, Prostate Cancer, Hemotological Tumor, Non-Hodgkin Lymphoma, Others

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. AbbVie Inc
  2. Amgen Inc
  3. AstraZeneca Plc
  4. Complix NV
  5. Les Laboratoires Servier SAS
  6. Takeda Pharmaceutical Co Ltd
  7. Warp Drive Bio Inc

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Overview


Highlights of The Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. AZD-5991
    2. FL-118
    3. S-64315
    4. UMI-77
    5. Others
  1. By Application:

    1. Ovarian Cancer
    2. Prostate Cancer
    3. Hemotological Tumor
    4. Non-Hodgkin Lymphoma
    5. Others
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Induced myeloid leukemia cell differentiation protein Mcl 1 is a protein that is found in the blood and bone marrow. It helps to control the growth of leukemia cells.

Some of the major players in the induced myeloid leukemia cell differentiation protein mcl 1 market are AbbVie Inc, Amgen Inc, AstraZeneca Plc, Complix NV, Les Laboratoires Servier SAS, Takeda Pharmaceutical Co Ltd, Warp Drive Bio Inc.

                                            
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Overview    4.1 Introduction       4.1.1 Market Taxonomy       4.1.2 Market Definition       4.1.3 Macro-Economic Factors Impacting the Market Growth    4.2 Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Dynamics       4.2.1 Market Drivers       4.2.2 Market Restraints       4.2.3 Market Opportunity    4.3 Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market - Supply Chain Analysis       4.3.1 List of Key Suppliers       4.3.2 List of Key Distributors       4.3.3 List of Key Consumers    4.4 Key Forces Shaping the Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market       4.4.1 Bargaining Power of Suppliers       4.4.2 Bargaining Power of Buyers       4.4.3 Threat of Substitution       4.4.4 Threat of New Entrants       4.4.5 Competitive Rivalry    4.5 Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Size & Forecast, 2020-2028       4.5.1 Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Size and Y-o-Y Growth       4.5.2 Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Absolute $ Opportunity

Chapter 5 Global  Market Analysis and Forecast by Type
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities by Type
      5.1.2 Basis Point Share (BPS) Analysis by Type
      5.1.3 Absolute $ Opportunity Assessment by Type
   5.2  Market Size Forecast by Type
      5.2.1 AZD-5991
      5.2.2 FL-118
      5.2.3 S-64315
      5.2.4 UMI-77
      5.2.5 Others
   5.3 Market Attractiveness Analysis by Type

Chapter 6 Global  Market Analysis and Forecast by Applications
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities by Applications
      6.1.2 Basis Point Share (BPS) Analysis by Applications
      6.1.3 Absolute $ Opportunity Assessment by Applications
   6.2  Market Size Forecast by Applications
      6.2.1 Ovarian Cancer
      6.2.2 Prostate Cancer
      6.2.3 Hemotological Tumor
      6.2.4 Non-Hodgkin Lymphoma
      6.2.5 Others
   6.3 Market Attractiveness Analysis by Applications

Chapter 7 Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Analysis and Forecast by Region
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities by Region
      7.1.2 Basis Point Share (BPS) Analysis by Region
      7.1.3 Absolute $ Opportunity Assessment by Region
   7.2 Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Size Forecast by Region
      7.2.1 North America
      7.2.2 Europe
      7.2.3 Asia Pacific
      7.2.4 Latin America
      7.2.5 Middle East & Africa (MEA)
   7.3 Market Attractiveness Analysis by Region

Chapter 8 Coronavirus Disease (COVID-19) Impact 
   8.1 Introduction 
   8.2 Current & Future Impact Analysis 
   8.3 Economic Impact Analysis 
   8.4 Government Policies 
   8.5 Investment Scenario

Chapter 9 North America  Analysis and Forecast
   9.1 Introduction
   9.2 North America  Market Size Forecast by Country
      9.2.1 U.S.
      9.2.2 Canada
   9.3 Basis Point Share (BPS) Analysis by Country
   9.4 Absolute $ Opportunity Assessment by Country
   9.5 Market Attractiveness Analysis by Country
   9.6 North America  Market Size Forecast by Type
      9.6.1 AZD-5991
      9.6.2 FL-118
      9.6.3 S-64315
      9.6.4 UMI-77
      9.6.5 Others
   9.7 Basis Point Share (BPS) Analysis by Type 
   9.8 Absolute $ Opportunity Assessment by Type 
   9.9 Market Attractiveness Analysis by Type
   9.10 North America  Market Size Forecast by Applications
      9.10.1 Ovarian Cancer
      9.10.2 Prostate Cancer
      9.10.3 Hemotological Tumor
      9.10.4 Non-Hodgkin Lymphoma
      9.10.5 Others
   9.11 Basis Point Share (BPS) Analysis by Applications 
   9.12 Absolute $ Opportunity Assessment by Applications 
   9.13 Market Attractiveness Analysis by Applications

Chapter 10 Europe  Analysis and Forecast
   10.1 Introduction
   10.2 Europe  Market Size Forecast by Country
      10.2.1 Germany
      10.2.2 France
      10.2.3 Italy
      10.2.4 U.K.
      10.2.5 Spain
      10.2.6 Russia
      10.2.7 Rest of Europe
   10.3 Basis Point Share (BPS) Analysis by Country
   10.4 Absolute $ Opportunity Assessment by Country
   10.5 Market Attractiveness Analysis by Country
   10.6 Europe  Market Size Forecast by Type
      10.6.1 AZD-5991
      10.6.2 FL-118
      10.6.3 S-64315
      10.6.4 UMI-77
      10.6.5 Others
   10.7 Basis Point Share (BPS) Analysis by Type 
   10.8 Absolute $ Opportunity Assessment by Type 
   10.9 Market Attractiveness Analysis by Type
   10.10 Europe  Market Size Forecast by Applications
      10.10.1 Ovarian Cancer
      10.10.2 Prostate Cancer
      10.10.3 Hemotological Tumor
      10.10.4 Non-Hodgkin Lymphoma
      10.10.5 Others
   10.11 Basis Point Share (BPS) Analysis by Applications 
   10.12 Absolute $ Opportunity Assessment by Applications 
   10.13 Market Attractiveness Analysis by Applications

Chapter 11 Asia Pacific  Analysis and Forecast
   11.1 Introduction
   11.2 Asia Pacific  Market Size Forecast by Country
      11.2.1 China
      11.2.2 Japan
      11.2.3 South Korea
      11.2.4 India
      11.2.5 Australia
      11.2.6 South East Asia (SEA)
      11.2.7 Rest of Asia Pacific (APAC)
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 Asia Pacific  Market Size Forecast by Type
      11.6.1 AZD-5991
      11.6.2 FL-118
      11.6.3 S-64315
      11.6.4 UMI-77
      11.6.5 Others
   11.7 Basis Point Share (BPS) Analysis by Type 
   11.8 Absolute $ Opportunity Assessment by Type 
   11.9 Market Attractiveness Analysis by Type
   11.10 Asia Pacific  Market Size Forecast by Applications
      11.10.1 Ovarian Cancer
      11.10.2 Prostate Cancer
      11.10.3 Hemotological Tumor
      11.10.4 Non-Hodgkin Lymphoma
      11.10.5 Others
   11.11 Basis Point Share (BPS) Analysis by Applications 
   11.12 Absolute $ Opportunity Assessment by Applications 
   11.13 Market Attractiveness Analysis by Applications

Chapter 12 Latin America  Analysis and Forecast
   12.1 Introduction
   12.2 Latin America  Market Size Forecast by Country
      12.2.1 Brazil
      12.2.2 Mexico
      12.2.3 Rest of Latin America (LATAM)
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Latin America  Market Size Forecast by Type
      12.6.1 AZD-5991
      12.6.2 FL-118
      12.6.3 S-64315
      12.6.4 UMI-77
      12.6.5 Others
   12.7 Basis Point Share (BPS) Analysis by Type 
   12.8 Absolute $ Opportunity Assessment by Type 
   12.9 Market Attractiveness Analysis by Type
   12.10 Latin America  Market Size Forecast by Applications
      12.10.1 Ovarian Cancer
      12.10.2 Prostate Cancer
      12.10.3 Hemotological Tumor
      12.10.4 Non-Hodgkin Lymphoma
      12.10.5 Others
   12.11 Basis Point Share (BPS) Analysis by Applications 
   12.12 Absolute $ Opportunity Assessment by Applications 
   12.13 Market Attractiveness Analysis by Applications

Chapter 13 Middle East & Africa (MEA)  Analysis and Forecast
   13.1 Introduction
   13.2 Middle East & Africa (MEA)  Market Size Forecast by Country
      13.2.1 Saudi Arabia
      13.2.2 South Africa
      13.2.3 UAE
      13.2.4 Rest of Middle East & Africa (MEA)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Middle East & Africa (MEA)  Market Size Forecast by Type
      13.6.1 AZD-5991
      13.6.2 FL-118
      13.6.3 S-64315
      13.6.4 UMI-77
      13.6.5 Others
   13.7 Basis Point Share (BPS) Analysis by Type 
   13.8 Absolute $ Opportunity Assessment by Type 
   13.9 Market Attractiveness Analysis by Type
   13.10 Middle East & Africa (MEA)  Market Size Forecast by Applications
      13.10.1 Ovarian Cancer
      13.10.2 Prostate Cancer
      13.10.3 Hemotological Tumor
      13.10.4 Non-Hodgkin Lymphoma
      13.10.5 Others
   13.11 Basis Point Share (BPS) Analysis by Applications 
   13.12 Absolute $ Opportunity Assessment by Applications 
   13.13 Market Attractiveness Analysis by Applications

Chapter 14 Competition Landscape 
   14.1 Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market: Competitive Dashboard
   14.2 Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market: Market Share Analysis, 2019
   14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.3.1 AbbVie Inc
      14.3.2 Amgen Inc
      14.3.3 AstraZeneca Plc
      14.3.4 Complix NV
      14.3.5 Les Laboratoires Servier SAS
      14.3.6 Takeda Pharmaceutical Co Ltd
      14.3.7 Warp Drive Bio Inc

Our Trusted Clients

Contact Us